Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa

Journal of Cystic Fibrosis

Volumn 10, Issue 4, 2011, Pages 234-242

  Wainwright, C E ^a   Quittner, A L ^b   Geller, D E ^c   Nakamura, C ^d   Wooldridge, J L ^e   Gibson, R L ^f   Lewis, S ^g   Montgomery, A B ^g  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MIAMI   (United States)

^c NEMOURS CHILDREN S HOSPITAL   (United States)

^d Cincinnati Children's Hospital Medical Center ^*  (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^g GILEAD SCIENCES INC   (United States)

Author keywords

Aztreonam; Cystic fibrosis; Inhaled antibiotics; Pseudomonas; Respiratory symptoms

Indexed keywords

AZTREONAM LYSINE; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE CONGESTION; PRESCHOOL CHILD; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINORRHEA; SCHOOL CHILD; SIDE EFFECT; SPUTUM; UPPER RESPIRATORY TRACT CONGESTION;

ADMINISTRATION, INHALATION; ADOLESCENT; ANTI-BACTERIAL AGENTS; AZTREONAM; CHILD; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; PLACEBOS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SEVERITY OF ILLNESS INDEX; THERAPEUTICS; YOUNG ADULT;

EID: 79958295843     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2011.02.007     Document Type: Article

References (17)

1. Gibson R.L., Burns J.L., Ramsey B.W. State of the art: pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003, 168:918-951.
2. Cystic Fibrosis Foundation Patient Registry 2008 annual data report to the center directors 2009, Cystic Fibrosis Foundation, Bethesda, MD.
3. Corey M., Edwards L., Levison H., Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997, 131:809-814.
4. Flume P.A., O'Sullivan B.P., Robinson K.A., et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007, 176:957-969.
5. Heijermann H., Westerman E., Conway S., Touw D., Döring G. Consensus working group. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2009, 8:295-331.
6. Konstan M.W., Morgan W.J., Butler S.M., et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007, 151:134-139.
7. Prescribing information: Cayston® (aztreonam for inhalation solution) FDA web site:, accessed 24 Aug 2010. http://www.cayston.com/media/CAYSTON_prescribe_info.pdf.
8. McCoy K.S., Quittner A.L., Oermann C.M., et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008, 178:921-928.
9. Retsch-Bogart G.Z., Quittner A.L., Gibson R.L., et al. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest 2009, 135:1223-1232.
10. Oermann C.M., Retsch-Bogart G.Z., Quittner A.L., et al. An 18-month study, AIR-CF3, of the safety and improvement in pulmonary function and respiratory symptoms with repeated courses of aztreonam for inhalation solution in patients with cystic fibrosis and airway Pseudomonas aeruginosa. Pediatr Pulmonol 2010, 45:1121-1134.
11. Quittner A.L., Buu A., Messer M.A., Modi A.C., Watrous M. Development and validation of the cystic fibrosis questionnaire in the United States: a health related quality of life measure for cystic fibrosis. Chest 2005, 128:2347-2354.
12. Wainwright C., Nakamura C., Geller D., Montgomery A.B. A double-blind, multinational, randomized, placebo-controlled trial evaluating aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF), mild lung disease and P. aeruginosa (PA) [Abstract 81]. J Cyst Fibros 2010, 9(Suppl 1):S22.
13. American Thoracic Society Committee on Diagnostic Standards for Non-Tuberculous Respiratory Diseases Standardization of spirometry 1994 update. Am J Respir Crit Care Med 1995, 152:1107-1136.
14. Knudson R.J., Lebowitz M.D., Holberg C.J., Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983, 127:725-734.
15. Retsch-Bogart G.Z., Burns J.L., Otto K.L., et al. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2008, 43:47-58.
16. Murphy T.D., Anbar R.D., Lester L.A., et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol 2004, 38:314-320.
17. Amin R., Subbarao P., Jabar A., et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax 2010, 65:379-383.